VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - ExecEdge

Now Reading:

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

Exec-Edge

Full Article 40 second read

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

40 second read

By Karen Roman

VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation.

“Today’s news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio,” said Christoph Erkel, Ph.D., VERAXA’s Vice President Research and Development. “Initiating cell line development with ATUM is an important next step for our lead BiTAC-TCE program following the encouraging preclinical data we presented at AACR.”